A Japanese newspaper claims that the pharma giant funded flawed research that revealed extra health benefits for one of its top-selling drugs.
Advertisement
The Scientist
Most Recent
As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?
Pharma company publishes a list of 17 companies known to have sold the incorrect isomer of the kinase inhibitor bosutinib.
An incorrect isomer of the kinase inhibitor bosutinib is circulating in the biomedical research community, potentially throwing doubt on study results.
Legislation proposes speeding certain drug applications submitted to the US Food and Drug Administration.
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
